Interview with Dr. Jordi Monés, Director of the Institut de la Màcula
“We are experiencing spectacular developments in the fight against some types of blindness” said Dr. Jordi Mones.
In an interview published in Expansion last Friday 28th September, Dr. Jordi Mones explained what the treatment of AMD consists of, and new developments in the fight against some kinds of blindness.
Dr. Mones reminded us that “The first milestone was set in 2005 when a series of anti-VEGF (antivascular endothelial growth factor that is an essential molecule for the formation of veins and arteries) products appeared. With these medicinal products (ranibizumab, aflibercept, bevacizumab) we managed to detain the illness in three out of every four patients, and one in three experienced an improvement. But incredibly, now seven years later on even more progress has been made and we find ourselves in a new situation, which we, as investigators at the Barcelona Macula Foundation and the Institut de la Macula, have helped to bring about.”
The Director of the l’Institut de la Macula also described the latest studies which this centre has participated in. From the Institute we have coordinated Spanish sites that have participated in a study which was conducted on 449 patients in countries from both America and Europe. Hence, after combining the already proven anti-VEGF agent ranibizumab with another experimental product, an antiplatelet-derived growth factor (Fovista), we have improved on the conventional monotherapy, with an additional benefit of 62% for the patient.
The study shows that, after six months of treatment, consisting in injecting the medicinal product into the eye interior with local anaesthetics once a month, there is a 62% greater improvement in sight with the combined administration of the two products compared to the administration of ranibizumab alone. This is a surprising result that benefits the patients enormously and means that an increasing number of patients can read again.”